A British cervical cancer trial revealed promising results by using chemotherapy drugs at specific times to enhance survival rates.
The study reported a remarkable 35% reduction in the mortality rate. Researchers randomized 500 female patients into two groups: one received chemoradiation therapy alone, while the other received induction chemotherapy using carboplatin and paclitaxel, followed by the same chemoradiation therapy in week 7.
After a 5-year follow-up, 80% of the women receiving the combination chemo-drug and radiotherapy were still alive, with 73% showing no cancer recurrence. The conclusion of the trial suggests this combination should become the new standard of treatment.
These findings suggest that administering additional rounds of chemotherapy before other treatments, such as surgery and radiotherapy, can significantly reduce the chances of cancer returning.